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Iliac Artery Endofibrosis 
Robert J. Hinchliffe 
 
The investigation and management of peripheral arterial diseases in elderly patients, 
frequently with multiple co-morbidities, are familiar to all vascular surgeons. These patients 
are often at high risk of limb loss and premature death and intervention is easy to justify. In 
fact vascular techniques have advanced rapidly to meet the challenges in this population and 
it is now possible to offer medical therapies and interventions to preserve life and limb even 
in the most elderly and frail patients. 
Vascular disease in younger patients, especially those who are elite athletes represents a 
different challenge. Healthcare professionals including physical therapists and doctors in 
primary care and sports medicine rarely manage conditions such as iliac artery endofibrosis. 
Most vascular surgeons infrequently manage the condition. Patients presenting to a vascular 
surgeon with suspected iliac artery endofibrosis often do so against this backdrop of delay or 
failure to suspect or diagnose vascular disease. Consequently patients frequently present late 
with persistent and frequently debilitating. They are often frustrated by their symptoms and 
impaired athletic performance and have been investigated extensively by an inter-disciplinary 
group of healthcare professionals usually focussing on musculoskeletal pathology. They may 
have seen neurologists and even psychologists.  
Most athletes experience minor injuries from which they make a rapid and full recovery. 
Therefore the expectations of these young people and those associated with their welfare is 
high. Invariably they expect a rapid and perfect solution with early return to competitive 
sport. For many it is unfathomable that they may have a career threatening disease. 
The indications and outcomes of vascular interventions in younger patients are concerning 
because they remain largely unchartered territory. The effectiveness of vascular surgery in 
preventing amputation and death is difficult to dispute in older patients with advanced 
disease. However, its effectiveness in restoring perfect health and improving athletic 
performance remains to be established. The demands placed on a vascular surgical 
reconstruction in an athlete far outweigh any that might be considered necessary or normal 
for most patients within the realms of standard clinical practice. And the durability of any 
surgical repair will, perhaps be required for half a century or more. These factors undoubtedly 
explain why many vascular surgeons feel a certain reluctance to offer surgery to the youngest 
patients with mild or moderate (in many instances only haemodynamically significant under 
the most severe exercise load) vascular disease unless there is clear evidence that the 
underlying disease process is likely to be life or limb threatening.  
Published data on the outcomes of surgical intervention in the short term are sparse and 
almost non-existent beyond 5 years (1). There have even been reports of deaths and major 
(limb threatening) complications following surgery. And yet there appear to be an increasing 
number of patients being offered surgery. For patients there are clearly a number of complex 
motives not least financial ones for professional athletes. But given the requirements and 
demands placed on vascular reconstructions it is hard to understand why any sensible 
vascular surgeon would recommend vascular reconstruction for a young otherwise perfectly 
healthy person with iliac artery endofibrosis. 
There are some reasons why iliac artery endofibrosis appear to be increasing. Cycling in 
particular is a booming sport with increasing participation with high training loads and 
extreme aerodynamic cycling positions may play a role. There is an increasing awareness of 
the problem especially among the professional peloton. The detection rate may also be 
increasing in those presenting to vascular surgeons following attempts have been made to 
standardise (non-invasive) diagnostic algorithms to detect the disease in specialist units (2, 3). 
The true incidence especially in elite athletes may just be a lot higher than previously 
recognised with haemodynamic evidence of endofibrosis in some 10-20% of elite athletes 
(4). And there is some suggestion that surgeons have become more liberal in their indications 
for surgery. This may be consequent to observations of progression of endofibrotic disease in 
those who continue athletic activity and a smattering of reports of acute limb ischaemia due 
to dissection and occlusion of external iliac arteries (1, 5). Preliminary outcome data from 
specialist units appear encouraging with few serious complications and most athletes 
appearing to resume competitive sport (6, 7). 
There are difficulties for surgeons and patients alike in that there appear to be no viable 
alternatives to relieve symptoms other than exercise cessation or surgery. Conservative 
therapies such as the use of biomechanics and physiotherapy appear to be largely ineffective 
and interventions that may prove useful for peripheral artery disease due to atherosclerosis 
such as supervised exercise therapy and angioplasty / stenting are either ineffective or contra-
indicated. For many exercise cessation is the most reasonable management strategy. 
Persuading elite athletes and more surprisingly ‘weekend warriors’ that this is the most 
sensible decision should not be underestimated and may be extremely difficult. Others may 
wish to continue to exercise if their symptoms are stable.  
Until recently efforts to understand iliac artery endofibrosis have been limited to a handful of 
specialist centres who have reported on their own diagnostic algorithms and surgical 
outcomes (3, 8). The INSITE Group have performed a consensus study on the current 
diagnosis and management of iliac endofibrosis (9). This is a useful first step to draw together 
some of the disparate opinions on the diagnosis, natural history and management of the 
condition. However, much remains to be done if we are going to standardise the overall 
management of the condition and therefore improve patient outcomes and prevent 
unnecessary patient harm and improve outcomes. Key issues include delineating the natural 
history of the disease and identifying those at highest risk of developing the condition and 
particularly its complications.  
A disease registry for patients with iliac endofibrosis will prove invaluable to patients and 
surgeons alike. It is no longer acceptable to operate on patients and fail to record their 
outcomes for external scrutiny and the promotion of clinical research. The use of these sorts 
of registers has greatly improved our understanding of a number of other rare diseases (10). 
And in some cases it has also been possible to perform randomised trials. 
For elite cyclists and triathletes in particular, iliac artery endofibrosis could be considered to 
amount to an occupational disease. And therefore both athletes and their governing bodies 
should consider the wider impact of the disease on their sport and members. Both groups 
have an important role to play in promoting and contributing to research in the field. Only 
with the support of athletes, the medical teams that manage them and governing bodies will it 
be possible to perform the necessary clinical research to improve care. 
Perhaps it is time for vascular surgeons to look to the example set in sports cardiology. 
Sudden cardiac deaths are shocking in young athletes. These experiences have galvanised the 
sporting community to work with cardiologists to generate the necessary research to identify 
those at highest risk of sudden death and develop methods to mitigate the risk. Few would 
dispute the progress that has been made in sports cardiology including the delivery of 
national cardiac screening programs. These advances could be replicated in peripheral arterial 
diseases. 
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